Introduction
mutations in PI-3 kinase or its downstream effector, PKB/Akt, or by the mutational inactivation, or loss of the tumor suppressor, PTEN (Cantley and Neel, 1999) . The constitutive upregulation Angiogenesis plays a critical role in cancer progression (Hanahan and Weinberg, 2000) . Tumor growth and metastasis have of expression of VEGF by tumor cells is felt to be a major contributor to tumor angiogenesis (Ferrara, 2002) . been shown to be dependent on angiogenesis, and inhibition of tumor angiogenesis by selectively inhibiting the growth, survival, VEGF expression is regulated at the level of transcription by a variety of transcription factors that include AP-1, NF-B, and migration of endothelial cells is perceived as an attractive, nontoxic means of regulating tumor progression (Kerbel, 1991) .
and hypoxia-inducible factor-1␣ (HIF-1␣) (Huang et al., 2000; Ryan et al., 1998; Damert et al., 1997) . The major physiological A variety of proteins have been identified as potential targets of antiangiogenesis therapy, and despite poor results in clinical stimulus for VEGF expression is hypoxia, resulting in the transcriptional induction of the VEGF gene by HIF-1␣ (Forsythe et trials of some of the antiangiogenic strategies (Kerbel and Folkman, 2002) , the potential of antiangiogenic therapy continues Carmeliet et al., 1998; Ryan et al., 1998) , which is a heterodimeric transcription factor composed of HIF-1␣ and to be an attractive means of cancer control.
One of the key mediators of angiogenesis is vascular endo-HIF-1␤ subunits (Jiang et al., 1996) . The hypoxia-mediated stimulation of HIF-1␣ expression is regulated by the inhibition of thelial cell growth factor (VEGF), which can promote the proliferation, survival, and migration of endothelial cells and is essential ubiquitin-mediated degradation and consequent stabilization of the HIF-1␣ subunit under hypoxic conditions. As a result, HIFfor blood vessel formation (Ferrara, 2002) . VEGF is expressed by activated endothelial cells, but more importantly for tumor 1␣ accumulates, dimerizes with HIF-1␤, and activates transcription of target genes, including VEGF (reviewed in Harris, 2002) . angiogenesis, VEGF expression and secretion are stimulated in tumor cells by activation of oncogenes such as Ras (Rak et al., Recently, however, the expression of VEGF via the activation of the PI-3 kinase pathway has also been shown to be mediated 2000), as well as by the activation of the PI-3 kinase pathway (Jiang et al., 2001; Fukuda et al., 2002) , which has inherent by HIF-1␣ (Jiang et al., 2001; Fukuda et al., 2002) . Signaling via receptor tyrosine kinases induces HIF-1␣ expression by an oncogenic properties. The PI-3 kinase pathway can be constitutively activated via autocrine growth factors by constitutively independent mechanism involving the stimulation of increased rates of HIF-1␣ protein synthesis via PI-3 kinase-dependent activated growth factor receptors such as Erb-B2, by activating stimulation of PKB/Akt and mTOR/FRAP, which activates the translational regulatory protein eIF-4E binding protein 1 (4E-BP1) and p70 S6 kinase (Fukuda et al., 2002; Laughner et al., 2001; Gingras et al., 2001; Peterson et al., 1999) . These findings indicate that HIF-1␣ regulates both hypoxia-and growth factorinduced VEGF expression.
One of the components of the PI-3 kinase pathway, immediately upstream of PKB/Akt, is integrin-linked kinase (ILK) (Hannigan et al., 1996; Wu and Dedhar, 2001; Troussard et al., 2003) . ILK can interact with the cytoplasmic domain of ␤-integrin subunits and is activated by both integrin activation as well as growth factors (Wu and Dedhar, 2001) . ILK is a PI-3 kinasedependent kinase (Persad et al., 2001a; Delcommenne et al., 1998) and is an upstream regulator of the phosphorylation of PKB/Akt on serine 473 (Troussard et al., 2003; Persad et al., 2000 Persad et al., , 2001a Lynch et al., 1999; Delcommenne et al., 1998) , one of the two phosphorylation sites required for the full activation of PKB/Akt. Overexpression of ILK induces anchorage-independent cell growth and suppression of anoikis and promotes hyperplasia and tumor formation in vivo (Wu and Dedhar, 2001 ). ILK activity is also constitutively activated in PTEN null cancer cells, and the constitutive activation of PKB/Akt in such cells is inhibited upon inhibition of ILK activity (Persad et al., 2000) . ILK also promotes cell migration and invasion (Persad and Dedhar, 2003) . Because of these oncogenic properties of ILK, we decided to explore the potential role of ILK in promoting tumor angiogenesis. We wanted to determine whether ILK is involved in the stimulation of expression of VEGF in tumor cells and secondly whether ILK is required for VEGF-mediated endothelial cell migration and formation of blood vessels.
In this paper, we report that overexpression of ILK stimulates VEGF expression in a PKB/Akt-and HIF-1␣-dependent manner and that inhibition of ILK expression or activity in VEGF-expressing prostate cancer cells (DU145 and PC3) results in dramatic xenograft tumor model. Our results demonstrate an important and essential role of ILK in two key aspects of tumor angiogenesis, VEGF expression by tumor cells and VEGF-stimulated blood vessel formation, and suggest that ILK may be a promising pression also resulted in the stimulation of VEGF expression. therapeutic target for the inhibition of tumor angiogenesis.
As shown in Figure 1A , the expression of both isoforms of VEGF is markedly stimulated in the ILK-overexpressing clone of IECResults 18 cells (ILK-13, A1a3), as compared to control clones expressing the E359K kinase-deficient ILK dominant-negative (ILK-DN, Overexpression of ILK stimulates VEGF expression GH31RH) or antisense-ILK (ILK-14) (Novak et al., 1998 ; Hanniin a PKB/Akt-and HIF-1␣-dependent manner gan et al., 1996) . In addition, the data in Figure 1A also show We have previously demonstrated that overexpression of ILK markedly increased phosphorylation of PKB/Akt on serine 473 in IEC-18 rat intestinal epithelial cells results in anchorage-indein the absence of any changes in PKB/Akt expression. Since pendent cell cycle progression, tumorigenicity in nude mice, one of the major transcriptional regulators of the VEGF gene is activation of PKB/Akt, inhibition of GSK-3, and stimulation of hypoxia-inducible factor-1␣ (HIF-1␣), we transfected the differ-AP-1, NF-B, and ␤-catenin/LEF transcription factors (reviewed ent IEC-18 clones described above with a HIF-1 response elein Wu and Dedhar, 2001 ). Overexpression of a kinase-deficient ment fused to a green fluorescence protein (GFP) reporter mutant of ILK, or ILK antisense cDNA, did not result in the (HRE:GFP) (Ruan and Deen, 2001) . As shown in Figure 1A, (Radeva et al., 1997) , and inhibition of ILK expression by siRNA inhibits cyclin D1 expression (Troussard et al., 2003) . As shown in Figure 1B (Davies et al., 1999; Stambolic et al., 1998) . We have previously shown that ILK activity is also constitutively activated in these cells and that inhibition of ILK activity suppresses PKB/ Akt activity in these PTEN null cells (Persad et al., 2000) . VEGF expression has been shown to be constitutively elevated in PC3 cells (Jiang et al., 2001 ). Because we had found that ILK stimulated VEGF expression (Figure 1 ), we wanted to determine whether inhibition of ILK activity in PC3 cells resulted in the inhibition of VEGF expression. As shown in Figure 2A , inhibition of ILK activity by transfection of kinase-deficient, ILK-DN (E359K) (Persad et al., 2000) , or wild-type PTEN resulted in inhibition of VEGF expression at the protein level as determined by Western blotting. In addition, the expression of HIF-1␣ protein is also substantially inhibited by DN-ILK and PTEN ( Figure  2A ). As expected, DN-ILK also inhibited phosphorylation of PKB/Akt on serine 473 ( Figure 2A ). Expression of dominantnegative ILK and PTEN also inhibited the activity of the HIF-1 response element (HRE), as shown in Figure 2C , suggesting that the upregulation of VEGF expression in these cells is likely due to the ILK-mediated upregulation of HIF-1␣ expression. phosphorylation and activation (Troussard et al., 2003) . We ILK-specific siRNA (Troussard et al., 2003) . As shown in Figure   cells sion in PC3 cells. This was associated with a suppression of phosphorylation of PKB/Akt on serine 473. Expression of PKB/ Akt was not affected ( Figure 2B ). Furthermore, ILK siRNA-mediated knockdown of ILK also resulted in significant inhibition of expression of both HIF-1␣ and VEGF protein ( Figure 2B ). It has been recently shown that PKB/Akt can regulate the expression of HIF-1␣ protein at the translational level by stimulating the phosphorylation of mTOR/FRAP, which is a regulator of protein synthesis (Gingras et al., 2001; Peterson et al., 1999) . We therefore wanted to determine whether the ILK-mediated expression of HIF-1␣ and VEGF also involved mTOR/FRAP. As shown in Figure 2B , siRNA-mediated knockdown of ILK resulted in the inhibition of mTOR/FRAP phosphorylation on serine 2448, concomitant with the inhibition of the PKB/Akt phosphorylation. The expression of mTOR/FRAP protein was not affected by the knockdown of ILK. These data suggest that in the PC3 cells, the constitutive activation of ILK drives VEGF expression most likely via HIF-1␣ through the activation of PKB/Akt and mTOR/ FRAP, resulting in increased translation of HIF-1␣ protein. This is further substantiated by the observation that transfection of a dominant-negative HIF-1␣ construct into PC3 cells almost completely inhibits VEGF expression as well as HRE activity ( Figure 2C ).
Pharmacological inhibition of ILK activity results in the inhibition of HIF-1␣ and VEGF expression in prostate cancer cells
We have identified highly selective small molecule inhibitors of ILK activity. These ATP competitive inhibitors have been extensively characterized, and shown to inhibit ILK activity and the activation of all of the downstream effectors of ILK (Cruet-Hennequart et al., 2003; Mills et al., 2003; Persad et al., 2000 Persad et al., , 2001a Persad et al., , 2001b Tan et al., 2001 Troussard et al., 2000) . The inhibitors are equally effective and specific as ILK inhibition by dominant-negative ILK and ILK siRNA (Persad et al., 2001a (Persad et al., , 2001b Troussard et al., 2003) . We therefore wanted to determine whether exposure of human prostate cancer cells to the ILK inhibitor would also inhibit the expression of HIF-1␣ and the expression and synthesis of VEGF. As shown in Figure 3A , exposure of both PC3 and DU145 prostate cancer cells to the ILK inhibitor KP-392 (Persad et al., 2001a (Persad et al., , 2001b resulted in the inhibition of both HIF-1␣ and VEGF expression in a dose- expression of PKB/Akt. In addition, as shown in Figure 3B , not only VEGF cellular expression but also its secretion, as determined by an enzyme-linked immunosorbant assay (ELISA) of the conditioned cell media, are inhibited by the ILK inhibitor can result in substantial inhibition of the expression of both KP-392. In contrast to PC3 cells, VEGF expression is not com-HIF-1␣ and VEGF, suggesting that ILK may be an important pletely inhibited by the ILK inhibitor in DU145 cells, despite therapeutic target for the inhibition of expression of the angiosubstantial inhibition of HIF-1␣ expression. This suggests cell genic factor, VEGF. type differences in the regulation of VEGF expression.
In Figure 3C , we demonstrate that HIF-1␣ expression is ILK regulates VEGF-mediated endothelial cell stimulated by serum in serum-starved PC3 cells and that inhibimigration and blood vessel formation tion of ILK as well as PI-3 kinase with the respective pharma-VEGF stimulates endothelial cell survival and migration and procological inhibitors KP-392 and LY294002 inhibits HIF-1␣ exmotes the formation of new blood vessels (Ferrara, 2002) . Since pression.
the activity of ILK is stimulated by various growth factors and Collectively, the data shown in Figures 2 and 3 demonstrate chemokines (Wu and Dedhar, 2001; Friedrich et al., 2002) and that ILK is a critical component of the constitutively activated ILK also promotes cell migration and invasion (Persad and Ded-PI-3 kinase-PKB/Akt signaling pathway resulting in the stimulahar, 2003), we wanted to determine whether ILK also played a role in VEGF-mediated endothelial cell migration and vascular tion of HIF-1␣ and VEGF. Inhibition of ILK expression or activity A: ILK kinase activity is stimulated by VEGF in HUVEC. Cells were starved (24 hr) and exposed to the indicated amounts of VEGF and LY294002. The ILK kinase assay was carried out as described in the Experimental Procedures. This is a representation of three independent trials. B: Decrease in ILK activity reduces HUVEC invasion and migration toward VEGF. Two hours after HUVEC were seeded on the upper chamber, indicated amounts of KP-392 were added to this chamber, and the migration assay was performed and analyzed as described in Experimental Procedures. This graph represents the mean of three experiments Ϯ SD. C: Knockdown of ILK expression reduces HUVEC invasion and migration toward VEGF. Equal number of HUVEC transfected for 3 days with the indicated siRNA (25 nM) were seeded in the upper chamber. The experiment was performed as described in Experimental Procedures. This graph represents the mean of three experiments Ϯ SD. D: Immunoblot analysis with the indicated antibodies of RIPA lysate of transfected HUVEC (25 nM indicated siRNA) that were starved (24 hr) then exposed (24 hr) to VEGF (0 or 20 ng/ml) 2 days posttransfection. The graph represents relative HUVEC growth after above conditions, measured by WST-1/ECS assay. Results represent mean absorbance Ϯ SD. This is a representation of three experiments. Figure 4A , VEGF stimulates ILK VEGF-mediated HUVEC cell migration. Furthermore, inhibition of ILK expression in HUVEC cells by ILK siRNA also inhibited kinase activity in a dose-dependent manner in quiescent human umbilical vein endothelial cells (HUVEC). The stimulation of ILK VEGF-stimulated HUVEC cell migration ( Figure 4C ), demonstrating an essential role for ILK in the stimulation of endothelial activity by VEGF is dependent on PI-3 kinase activity since the VEGF stimulation of ILK activity is inhibited in the presence of the cell migration by VEGF. We also noted inhibition of cyclin D1 expression in the ILK siRNA transfected HUVEC cells ( Figure  PI-3 kinase inhibitor, LY294002. These data support previous studies showing ILK to be a PI-3 kinase-dependent kinase (Del-4D), indicating that inhibiting ILK may also inhibit VEGF-stimulated HUVEC cell proliferation. As shown in Figure 4D , HUVEC commenne et al., 1998; Lynch et al., 1999) and demonstrate that VEGF stimulates ILK activity in a PI-3 kinase-dependent cell proliferation in response to VEGF is inhibited in the ILK siRNA transfected cells. Cell viability in the ILK siRNA transmanner. We next determined whether ILK was required for the stimulation of VEGF-mediated cell migration of HUVEC cells.
morphogenesis. As shown in
fected cells was not significantly altered (data not shown). These data demonstrate an essential role of ILK in VEGF-mediated As shown in Figure 4B , VEGF stimulates the migration of HUVEC cells, and inhibition of ILK activity with the pharmacological HUVEC cell migration and proliferation. It has been demonstrated that VEGF promotes its own expression in endothelial ILK inhibitor, KP-392, results in a dose-dependent inhibition of cells via a positive autocrine loop involving HIF-1␣ expression mental Procedures. Both the KP-392 ILK inhibitor and the PI-3 kinase inhibitor LY294002 inhibited cell sprouting. Exposure of and activity (Stoeltzing et al., 2003; Zhong et al., 2000) . It is therefore interesting to note that VEGF-stimulated HIF-1␣ expression cells to 50 M KP-392 and 20 M LY294002 completely inhibited VEGF-induced HUVEC sprouting. In contrast, the MEK inin HUVEC cells is inhibited by ILK siRNA (Figure 4D ), suggesting that ILK is a component of this positive feedback loop.
hibitor, PD98059, did not have any significant inhibitory effect in this assay. The ILK inhibitor had only minor effects on HUVEC We next wanted to determine whether ILK is required for VEGF-mediated blood vessel formation. To evaluate this, we cell viability, and only at very high concentrations ( Figure 5A ). These data demonstrate that PI-3 kinase and ILK activities are initially utilized an in vitro endothelial cell sprouting assay. As shown in Figure 5A , VEGF significantly stimulated HUVEC capilrequired for VEGF-mediated vascular morphogenesis in vitro. Another assay that is frequently used for the demonstration lary sprouting, which was quantified as described in the Experi-function in response to VEGF, suggesting an essential role of ILK in blood vessel formation.
Inhibition of ILK activity inhibits VEGF-stimulated angiogenesis in vivo
We next wanted to determine whether inhibiting ILK activity resulted in the inhibition of VEGF-stimulated angiogenesis in vivo. We utilized a well-established assay for angiogenesis, the chicken chorioallantoic membrane (CAM) assay (Auerbach et al., 1975) , to determine the effects of the ILK inhibitor, KP-392. As shown in Figure 5C , inhibition of ILK activity had a significant effect on VEGF-stimulated blood vessel formation in vivo. In the CAM assay ( Figure 5C ), the incorporation of KP-392, compared to vehicle alone, together with VEGF resulted in the complete blockage of growth of blood vessels toward VEGF. It is interesting to note that the blood vessels are not lysed in the presence of KP-392, but rather they fail to grow toward VEGF and seem to be repelled away from VEGF, demonstrating that the inhibition of ILK predominantly inhibits the migration of endothelial cells and blood vessels toward VEGF.
Inhibition of tumor angiogenesis and suppression of tumor growth in ILK inhibitor-treated PC3 xenograft tumor model
The data presented above suggest that inhibition of ILK activity or expression should inhibit tumor angiogenesis and if PC3 tumor growth in vivo is dependent on tumor vascularization, then ILK inhibition should also induce tumor growth inhibition. To determine whether inhibition of ILK affected tumor angiogenesis and tumor growth in vivo, we established PC3 tumors in nude mice ( Figure 6 ) and treated mice with established tumors with the ILK inhibitor KP-307-2, an analog of KP-392. As shown in Figure 6A , there was a statistically significant effect on tumor vascularization as determined by microvessel density in anti-CD31 stained KP-307-2 treated and control tumor sections. In obvious side effects or weight loss (data not shown). These A: 7 days after dosing, one tumor from each mouse was harvested and data indicate that ILK is a mediator of prostate tumor angiogentumor vascular density was analyzed as described in Experimental Procedures. The bar graph shows the means of neovascular densities/field for esis, and therefore a target for antiangiogenic therapy. Angiogenesis is important in cancer progression and is one of the hallmarks of tumor metastasis (Hanahan and Weinberg, 2000) . A principal mediator of tumor angiogenesis is VEGF and a major transcriptional activator of the VEGF gene is HIF-1␣ of angiogenesis in vitro is the endothelial tube formation assay (Harris, 2002) . It has been reported that the PI-3 kinase/Akt in which endothelial cells placed on matrigel in the presence of signaling pathway mediates angiogenesis and the expression angiogenic factors results in the endothelial cells forming tubeof VEGF in cells by elevating the levels of HIF-1␣ protein in like structures morphologically similar to capillaries. This tube cells independent of hypoxic condition (Semenza, 2002) . This formation represents the contribution of cell survival, migration, hypoxia-independent stimulation of HIF-1␣ and VEGF in cancer and proliferation (Folkman and Haudenschild, 1980) . As shown cells can be mediated by autocrine or chronic stimulation by in Figure 5B , HUVEC cells cultured on matrigel in the presence growth factors such as IGF-1, constitutive activation of PI-3 of VEGF formed tube structures that were completely inhibited kinase, or the constitutive activation of PKB/Akt due to the by the ILK inhibitor, KP-392. At the same KP-392 concentrainactivation of the tumor suppressor, PTEN (Brazil et al., 2002 ; tions, significant inhibition of HUVEC cell migration and capillary Galetic et al., 1999) . Because ILK is PI-3 kinase dependent and sprout formation were observed ( Figures 4B and 5A) .
an upstream target of Akt/PKB and because an increase in These three different in vitro assays demonstrate that the ILK expression is positively correlated with prostate carcinoma grade (Graff et al., 2001 ), ILK was a likely candidate to be ininhibition of ILK activity has a dramatic effect on endothelial cell Figure 7 . Schematic representation of the cell signaling events leading to VEGF production in a prostate carcinoma cell and consequent effects on a neighboring endothelial cell Shown is our model for the production of VEGF in prostate carcinoma cell and the effects of VEGF on endothelial cell function. Phosphorylation of serine 473 of Akt/PKB by activated ILK in prostate cancer cells results in the full activation of PKB/Akt that promotes the phosphorylation of serine 2448 of mTOR/FRAP. This activates mTOR/ FRAP, which increases the levels of HIF-1␣ protein translation. HIF-1␣ protein combines with HIF-1␤ to form an active transcription factor. This heterodimer binds to the VEGF promoter and activates VEGF transcription, expression, and secretion. VEGF binds to its receptor on nearby endothelial cells and stimulates ILK activity. ILK regulates downstream targets involved in cell survival, proliferation, invasion migration, and sprout formation, which result in angiogenesis toward the VEGF gradient.
volved in the regulation of VEGF and HIF-1␣ expression through (Scandurro et al., 2001; Grimshaw and Mason, 2001 ), suggesting that ILK may also play a role in hypoxia-induced VEGF Akt/PKB activity regulation. In addition, the regulation of HIF-1␣ translational rate has been shown to be through the regulation of expression. Thus, the role of ILK in hypoxic tumors with constitutive activation of PI-3 kinase may be quite substantial. mTOR/FRAP, a downstream target of Akt/PKB (Fukuda et al., 2002) .
We have also shown here that ILK plays an essential role in VEGF-stimulated endothelial cell-mediated blood vessel forIn this paper, we have shown that in human prostate cancer cells, ILK is essential for the regulation of HIF-1␣ expression mation in vitro and in vivo (Figure 6 ). Migration and proliferation of human endothelial cells in response to VEGF are inhibited and the consequent production of VEGF. Functional inactivation of ILK by exposure to a highly selective chemical inhibitor, or upon inhibition of ILK activity or expression. Furthermore, the ability of VEGF-stimulated endothelial cells to form capillarystable or transient transfection of the ILK dominant-negative construct into cell models with high ILK activity, result in a like structures in vitro is also severely inhibited by inhibiting ILK activity. This inhibition appears to be due primarily to inhibition decrease in HIF-1␣ protein levels and VEGF expression. Furthermore, depletion of ILK protein by siRNA in PC3 cells effectively of cell migration and proliferation, both of which can be regulated by ILK in response to growth factors or engagement of decreases Akt/PKB and mTOR/FRAP phosphorylation, HIF-1␣ levels, and VEGF expression. These data suggest that in certain integrins (Wu and Dedhar, 2001; Cruet-Hennequart et al., 2003) . The inhibition of angiogenesis in vivo in the CAM assay by cancer cells, such as prostate carcinoma cells, ILK plays a crucial role in HIF-1␣ and VEGF expression via activation of inhibition of ILK suggests that the primary effect of ILK inhibition is on endothelial cell migration and ability to form vessels, as PKB/Akt and phosphorylation of mTOR/FRAP (Figure 7) . VEGF gene transcription can also be stimulated by the transcription there did not appear to be any obvious cell lysis in these assays. This agrees with our finding that HUVEC cell survival appears factors AP-1 and NF-B (Harris, 2002) . Since ILK has also been shown to regulate the activities of both of these transcription not to be affected as significantly as cell migration and proliferation upon ILK inhibition. Recent evidence from the systemic and factors (Troussard et al., 2000; , it is possible that in certain cell types ILK could regulate VEGF expression targeted knockout of ILK suggests an important role of ILK in cell adhesion and actin accumulation (Sakai et al., 2003) , via signaling pathways that activate these other transcription factors. Although in this study we have not ruled out the contriprocesses crucial for cell morphogenesis and migration, as well as in cell proliferation (Terpstra et al., 2003) . bution of AP-1 and NF-B in the ILK-mediated regulation of VEGF expression in the prostate cancer cell lines examined,
We have also shown here that inhibition of ILK with a highly selective ILK inhibitor results in the statistically significant supthe data presented here support a significant role of HIF-1␣ in the ILK regulation of VEGF expression. This is particularly true pression of tumor angiogenesis as well as tumor growth in a mouse xenograft model of PC3 tumor growth in SCID mice. for the PC3 cells in which inhibition of ILK expression or activity results in almost complete suppression of both HIF-1␣ and These data suggest that inhibitors of ILK activity may be considered as angiogenesis inhibitors effective for the suppression of VEGF expression. Furthermore, in the PTEN null PC3 cells in which the PI-3 kinase pathway and ILK are constitutively upregtumor angiogenesis. The integrins ␣ V ␤ 3 , ␣ V ␤ 5 , and ␣ 5 ␤ 1 have also been shown to ulated, transfection of dominant-negative HIF-1␣ results in substantial inhibition of VEGF expression. It is interesting to note be crucial regulators of endothelial cell function during angiogenesis (Hood and Cheresh, 2002; Eliceiri and Cheresh, 2001 ; that ILK mRNA has been shown to be upregulated by hypoxia Western blotting Friedlander et al., 1995) . Furthermore, angiogenesis inhibitors Cell lyses and Western blotting were carried out as previously described by such as endostatin and tumstatin have been shown to function us (Troussard et al., 2003; Cruet-Hennequart et al., 2003; Tan et al., 2001;  by inhibiting integrin function and signaling (Maeshima et al., Persad et al., 2001a , 2001b . The following antibodies were used in this study:
2002). Tumstatin has been shown to inhibit endothelial cell suranti-phosphoserine 473 PKB/Akt, anti-PKB/Akt, and anti-phosphoserine vival by binding to ␣ V ␤ 3 and inhibiting ␣ V ␤ 3 -metiated signaling 21/9-glycogen synthase kinase-3 (GSK-3) antibodies from New England to PKB/Akt (Maeshima et al., 2002) . Since ILK is also regulated (5 ϫ 10 4 cells) were added to the upper wells and allowed to attach for 2 DU145 cells were transfected with 4 l of Fugene reagent (Roche Molecular hr at 37ЊC. Increasing amounts of KP-392 and equivalent amounts of DMSO Biochemicals). Intestinal epithelial cells (IEC-18) were stably transfected with diluted in 100 l were added to the upper well for a complete volume of ILK wild-type (ILK-13 A1a3), ILK dominant-negative (ILK-DN GH31RH), or 300 l. The lower compartment was filled with F-12K medium containing 0 ILK antisense (ILK-14 antisense) (Hannigan et al., 1996) . The parental IECor 20 ng/ml VEGF. Chambers were incubated for 16 hr in a 5% CO 2 , 99% 18 cells were used as the control. These cells were cultured as previously humidity, and 37ЊC atmosphere. Cells on the under side of the filter were described (Delcommenne et al., 1998) . Human umbilical vein endothelial quantified by staining the cells with crystal violet, followed by counting the cells (HUVEC) (ATCC) were cultured as suggested by ATCC. ILK-13 A1a3 number of cells per magnified field of view (6 fields/membrane). and HUVEC cells were transfected with 6 l of Lipofectamine 2000 reagent (Life Technologies Inc.) according to the manufacturer's guidelines.
Cell viability and proliferation assay
The metabolic activity of cells was determined in vitro using the colorimetric Small interfering RNA (siRNA) cell proliferation/tetrazolium salt WST-1 reagent/Electro Coupling Solution PC3 cells were transfected with small interfering RNA (siRNA) that specifically (WST-1/ECS) assay kit (Chemicon International, California) according to targets the ILK gene (ILK-H or ILK-A) or nonsilencing control using 6 l of manufacturers instructions. The plate was incubated with the reagent for an Lipofectin in OPTI-MEM (GibcoBRL) overnight. The cells were passaged 36 additional 30 min to 1 hr and quantified by spectrophotometry (OD ϭ 450 hr after incubation in complete media and harvested 36 to 48 hr later as nm). All experiments were performed in triplicate. previously described (Troussard et al., 2003) . siRNA duplexes were synthesized by Xeragon Inc., MD. Sequences of the human ILK gene specifically
Immunohistochemical staining targeting the pH domain (ILK-H) (Troussard et al., 2003) and the integrin Tissues were frozen in compound-embedding medium (OCT; Miles Inc., binding domain (ILK-A) were chosen. The sequence of the DNA target of Indiana), and 10 m sections were collected on positively charged slides ILK-A is 5Ј-GACGCTCAGCAGACATGTGGA-3Ј. A nonsilencing siRNA (16 (Wax-It Histology Services Inc., B.C., Canada). Sections were fixed with cold base overlap with Thermotoga maritimia) was used as the control.
acetone and blocked with 3% hydrogen peroxidase, followed by 1% bovine serum albumin and normal rabbit serum. Sections were then incubated with Chemical inhibitors the anti-mouse CD31 antibody (BD Pharmingen) overnight at 4ЊC, followed Cells were exposed to the highly specific small molecule inhibitor  by incubation with a horseradish peroxidase conjugated anti-rat secondary Kinetek Pharmaceuticals) (Cruet-Hennequart et al., 2003; Mills et al., 2003;  antibody (Jackson Laboratories) for 1 hr at room temperature. The tissue Tan et al., 2001 Persad et al., 2000 Persad et al., , 2001a Persad et al., , 2001b and equivalent was washed three times with PBS in between each step. The antibody amounts of DMSO vehicle. PI-3 kinase inhibitor LY294002 (Calbiochem) localization was visualized with NOVARED substrate kit (Vector Laboratories, and MEK1 inhibitor PD98059 (Cell Signaling Technology) were dissolved in California), used as directed by manufacturer, and the slides were counterstained with hematoxylin. DMSO as the vehicle.
